Adverum Biotechnologies I... (ADVM)
| Bid | 3.75 |
| Market Cap | 86.54M |
| Revenue (ttm) | -2.59M |
| Net Income (ttm) | -93.78M |
| EPS (ttm) | -5.95 |
| PE Ratio (ttm) | -0.7 |
| Forward PE | -1.02 |
| Analyst | Buy |
| Ask | 4.97 |
| Volume | 253,122 |
| Avg. Volume (20D) | 202,441 |
| Open | 4.84 |
| Previous Close | 4.71 |
| Day's Range | 4.15 - 5.14 |
| 52-Week Range | 3.52 - 20.90 |
| Beta | 0.94 |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...
Analyst Forecast
According to 6 analyst ratings, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 561.06% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago · seekingalpha.com
Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD PatientsAdverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS...